IP Library Granted Patent US 10,228,326
Granted Patent B2
US 10,228,326 · App. 14/433,230 · Granted Mar 12, 2019

Immunoassay method utilizing surface plasmon

Inventors: Makiko Ootani (Tokyo, JP); Takatoshi Kaya (Inagi, JP)
Assignee: KONICA MINOLTA, INC.
G01N21/6428G01N21/553G01N21/648G01N33/53G01N33/54373
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,228,326
App. No.
14/433,230
Granted
Mar 12, 2019
Kind
B2
Abstract

At least an embodiment addresses the problem of providing a SPR (surface plasmon resonance) or SPFS (surface plasmon-field enhanced fluorescence spectroscopy) immunoassay, which enables the measurement of whole blood, undergoes little fluctuations in measurement values, and can measure whole blood, serum and plasma in a single apparatus. At least an embodiment solves the above-mentioned problem by a SPR or SPFS immunoassay, which is an immunoassay utilizing SPR or SPFS, including an absorbance measurement step of measuring an absorbance of a sample, a mode setting step of setting a mode that corresponds to the result of the absorbance measured in the absorbance measurement step, and one or multiple step(s) for which treatment condition(s) has/have been set in accordance with the mode set in the mode setting step.

Claims (21)

1. An immunoassay method utilizing surface plasmon, comprising:

an absorbance measurement step of measuring an absorbance of a sample,

a mode setting step of classifying the sample type of the sample according to the result of the absorbance measured in the absorbance measurement step, wherein the mode is a mode for a whole blood sample and a mode for a serum sample or a plasma sample,

a treatment condition setting step of setting a treatment condition according to the mode of the sample set in the mode setting step, for treating the sample in one or more reaction step(s) thereafter,

wherein a primary reaction step of the one or more reaction steps comprises forming a complex between a substance to be measured in the sample and a ligand, and

a surface plasmon measurement step for qualitatively or quantitatively analyzing the substance to be measured in the sample on a sensor substrate.

2. The immunoassay utilizing surface plasmon according to claim 1 , wherein the treatment condition is a number of times of washing in a washing step that is conducted after the primary reaction step, and, in the case when a labeling reaction step is conducted, before the labeling reaction step.

3. The immunoassay utilizing surface plasmon according to claim 1 , wherein the treatment condition is a dilution rate of a sample in a dilution step.

4. The immunoassay utilizing surface plasmon according to claim 1 , wherein the treatment condition is a time for the primary reaction step.

5. The immunoassay utilizing surface plasmon according to claim 2 , wherein the mode setting step is a step of setting a whole blood mode for a whole blood sample and a normal mode for a serum sample or a plasma sample, and the number of times of washing for the whole blood mode is more than that for the normal mode.

6. The immunoassay utilizing surface plasmon according to claim 3 , wherein the mode setting step is a step of setting a whole blood mode for a whole blood sample and a normal mode for a serum sample or a plasma sample, and the dilution rate for the whole blood mode is higher than that for the normal mode.

7. The immunoassay utilizing surface plasmon according to claim 4 , wherein the mode setting step is a step of setting the first mode of the sample as a whole blood mode for a whole blood sample and the second mode as a normal mode for a serum sample or a plasma sample, and the time for the primary reaction step in the whole blood mode is longer than that for the normal mode.

8. The immunoassay utilizing surface plasmon according to claim 1 , which is an immunoassay utilizing surface plasmon-field enhanced fluorescence spectroscopy.

9. An immunoassay system utilizing surface plasmon, wherein the immunoassay according to claim 1 is conducted.

10. The immunoassay utilizing surface plasmon according to claim 2 , wherein the treatment condition is a dilution rate of a sample in a dilution step.

11. The immunoassay utilizing surface plasmon according to claim 2 , wherein the treatment condition is a time for the primary reaction step.

12. The immunoassay utilizing surface plasmon according to claim 1 , which is an immunoassay utilizing surface plasmon-field enhanced fluorescence spectroscopy.

13. An immunoassay system utilizing surface plasmon, wherein the immunoassay according to claim 1 is conducted.

14. The immunoassay utilizing surface plasmon according to claim 3 , wherein the treatment condition is a time for the primary reaction step.

15. The immunoassay utilizing surface plasmon according to claim 2 , which is an immunoassay utilizing surface plasmon-field enhanced fluorescence spectroscopy.

16. An immunoassay system utilizing surface plasmon, wherein the immunoassay according to claim 2 is conducted.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2022
From: KONICA MINOLTA, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 059747/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2015
From: OOTANI, MAKIKO; KAYA, TAKATOSHI
To: KONICA MINOLTA, INC.
Reel/Frame 035322/0490 →
Priority Claims (1)
JP 2012-221362 · Oct 3, 2012 · national
Continuity (1)
Related Publication 20150260654A1 · Sep 17, 2015